Last reviewed · How we verify
A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment (Mel48)
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
Details
| Lead sponsor | Craig L Slingluff, Jr |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 45 |
| Start date | 2008-05 |
Conditions
- Intraocular Melanoma
- Malignant Conjunctival Neoplasm
- Melanoma (Skin)
Interventions
- incomplete Freund's adjuvant
- multi-epitope melanoma peptide vaccine
- tetanus toxoid helper peptide
- biopsy
Primary outcomes
- Features of lymphoid neogenesis at the replicate immunization site — Up to Day 85
Countries
United States